Last reviewed · How we verify
Withdrawal of furosemide
Withdrawal of furosemide allows restoration of normal fluid and electrolyte balance by discontinuing loop diuretic activity.
Withdrawal of furosemide allows restoration of normal fluid and electrolyte balance by discontinuing loop diuretic activity. Used for Management of furosemide-induced adverse effects (hypokalemia, dehydration, electrolyte imbalance), Clinical de-escalation in heart failure or edema management.
At a glance
| Generic name | Withdrawal of furosemide |
|---|---|
| Also known as | Lasix |
| Sponsor | Unity Health Toronto |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Furosemide is a loop diuretic that inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, promoting sodium, potassium, and water excretion. Withdrawal reverses this mechanism, reducing urinary losses and allowing fluid retention and electrolyte repletion. This is a clinical management strategy rather than a pharmacological intervention.
Approved indications
- Management of furosemide-induced adverse effects (hypokalemia, dehydration, electrolyte imbalance)
- Clinical de-escalation in heart failure or edema management
Common side effects
- Fluid retention / edema rebound
- Hyperkalemia (if potassium supplementation ongoing)
- Hypertension rebound
- Worsening heart failure (if indicated for diuresis)
Key clinical trials
- Aquapheresis Efficacy in Outpatients With Decompensated Heart Failure (NA)
- Non-invasive Fluid Management (NA)
- Treatment of Intermediate-stage Hepatocellular Carcinoma (PHASE3)
- Treatment of Advanced Hepatocellular Carcinoma (PHASE3)
- The Use of Furosemide in Patients on Dialysis (PHASE4)
- Effect of Furosemide Withdraw in Stable Chronic Heart Failure Outpatients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Withdrawal of furosemide CI brief — competitive landscape report
- Withdrawal of furosemide updates RSS · CI watch RSS
- Unity Health Toronto portfolio CI